Pharmacology of moclobemide
W Haefely1, W P Burkard, A Cesura
1Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Clinical Neuropharmacology
|January 1, 1993
Summary
Moclobemide, a reversible MAO-A inhibitor, effectively treats depression and cognitive impairment in animal models. It demonstrates antidepressant and neuroprotective effects without significant side effects, offering a promising therapeutic option.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA).
- The precise molecular mechanism of its enzyme inhibition is not fully understood.
- It influences neurotransmitter levels in the brain.
Purpose of the Study:
- To investigate the effects of moclobemide on monoamine oxidase A (MAO-A) inhibition kinetics and molecular mechanisms.
- To evaluate the behavioral and cognitive effects of moclobemide in animal models.
- To assess its neuroprotective potential and safety profile.
Main Methods:
- Enzyme kinetics studies for MAO-A inhibition.
- Assessment of monoamine and metabolite levels in rat brain.
- Evaluation in animal behavioral models, including stress-induced anhedonia.
- Testing for cognitive function improvement and neuroprotection in ischemia/hypoxia models.
Main Results:
- Moclobemide increases extracellular monoamines and decreases metabolites in rat brain.
- Chronic treatment showed no loss or accumulation of activity.
- Reversibility of MAO-A inhibition was confirmed in vitro and in vivo.
- Moclobemide demonstrated efficacy comparable to standard antidepressants in behavioral models.
- It improved impaired cognitive functions and showed neuroprotective effects.
Conclusions:
- Moclobemide exhibits complex MAO-A inhibition kinetics with reversible effects.
- It possesses antidepressant, cognitive-enhancing, and neuroprotective properties.
- The drug has a favorable safety profile, lacking anticholinergic effects and showing minimal tyramine interaction.
More Related Videos
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
06:04Frontal Disconnection for Treating Mild Malformation of Cortical Development with Oligodendroglial Hyperplasia in Epilepsy (MOGHE) in the Frontal Lobe
Published on: August 16, 2024
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:23Sedatives and Hypnotics: Overview
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:20Sedatives and Hypnotics Drugs: Barbiturates
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...